SCHEMBL15440468

SCHEMBL15440468

CCOC(=O)c1cccc(NC(=O)OC(C)(C)C)c1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
ALDH1A1 P00352 5/20 0.46
TDP1 Q9NUW8 3/20 0.46
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TSHR P16473 4/20 0.45
MAPK10 P53779 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
KDM4E B2RXH2 4/20 0.45
HSD17B10 Q99714 3/20 0.45
MAPK1 P28482 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CDC25A P30304 1/20 0.44
CDC25B P30305 1/20 0.44
CDC25C P30307 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6164753 0.87 KDM4E (0.52) LMNAALDH1A1TDP1TP53HTT
SCHEMBL28493853 0.85 KDM4E (0.60) LMNAALDH1A1TDP1TP53HTT
SCHEMBL29065716 0.83 LMNA (0.52) LMNAALDH1A1TDP1TP53HTT
SCHEMBL15440648 0.81 ALDH1A1 (0.42) LMNAALDH1A1TDP1TP53HTT
SCHEMBL15440643 0.80 CA12 (0.47) LMNATDP1KMT2AMEN1CYP1A2
SCHEMBL3984461 0.80 KDM4E (0.51) LMNAKMT2AKDM4ERXFP1POLB
SCHEMBL3248129 0.80 NPC1 (0.54) LMNAALDH1A1TDP1KMT2AMEN1
SCHEMBL6467966 0.80 GAA (0.46) ALDH1A1HTTTSHRKMT2AMEN1
SCHEMBL15440463 0.79 CA12 (0.45) LMNAALDH1A1HTTTSHRKMT2A
SCHEMBL15440466 0.79 RXFP1 (0.48) LMNAALDH1A1HTTTSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2877462-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS Celgene Corporation (US) 2015-06-03 EP claimed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 US claimed
WO-2014018866-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 WO claimed
EP-2877462-B1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2019-09-04 EP disclosed
US-9133161-B2 Processes for preparing isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2015-09-15 US disclosed
EP-2877462-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS Celgene Corporation (US) 2015-06-03 EP disclosed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 US disclosed
WO-2014018866-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS UGT1A1, CYP3A5, CYP3A7 LMNA 1684/4885ALDH1A1 347/4885TDP1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.